Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.
Thorax
; 76(7): 733-736, 2021 07.
Article
em En
| MEDLINE
| ID: mdl-33414242
ABSTRACT
Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1ß and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Escarro
/
Citocinas
/
Azitromicina
Tipo de estudo:
Guideline
/
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Thorax
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Austrália